Suppr超能文献

相似文献

1
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
Ophthalmology. 2014 Apr;121(4):936-45. doi: 10.1016/j.ophtha.2013.10.037. Epub 2014 Jan 7.
3
Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Am J Ophthalmol. 2020 Oct;218:225-241. doi: 10.1016/j.ajo.2020.05.029. Epub 2020 Jun 19.
5
Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
Ophthalmology. 2013 Sep;120(9):1835-42. doi: 10.1016/j.ophtha.2013.02.002. Epub 2013 May 1.
6
7
Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
Acta Ophthalmol. 2016 Aug;94(5):441-8. doi: 10.1111/aos.12964. Epub 2016 Apr 7.
8
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
Ophthalmology. 2012 Jul;119(7):1399-411. doi: 10.1016/j.ophtha.2012.04.015. Epub 2012 May 11.
9
Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
J Manag Care Spec Pharm. 2018 Jul;24(7):608-616. doi: 10.18553/jmcp.2018.24.7.608.

引用本文的文献

1
VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration.
Int J Mol Sci. 2025 May 22;26(11):4992. doi: 10.3390/ijms26114992.
2
Intravitreal therapy-success stories and challenges.
Wien Med Wochenschr. 2025 May;175(7-8):162-174. doi: 10.1007/s10354-024-01070-8. Epub 2025 Mar 3.
3
Facts, Dogmas, and Unknowns About Mitochondrial Reactive Oxygen Species in Cancer.
Antioxidants (Basel). 2024 Dec 19;13(12):1563. doi: 10.3390/antiox13121563.
6
Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
Med Decis Making. 2023 Oct-Nov;43(7-8):914-929. doi: 10.1177/0272989X231197772. Epub 2023 Sep 12.
8
[Patient-reported outcomes in head and neck cancer treatment: relevance, challenges, and benefit].
HNO. 2023 Sep;71(9):592-598. doi: 10.1007/s00106-023-01325-7. Epub 2023 Jul 8.
9
Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry.
Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1681-1690. doi: 10.1007/s00417-022-05952-8. Epub 2023 Jan 12.

本文引用的文献

3
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
Ophthalmology. 2012 Jul;119(7):1399-411. doi: 10.1016/j.ophtha.2012.04.015. Epub 2012 May 11.
4
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.
6
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
7
Cost effectiveness of treatments for wet age-related macular degeneration.
Pharmacoeconomics. 2011 Feb;29(2):107-31. doi: 10.2165/11585520-000000000-00000.
8
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.
9
Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
J Eval Clin Pract. 2012 Apr;18(2):247-55. doi: 10.1111/j.1365-2753.2010.01546.x. Epub 2010 Sep 16.
10
Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):467-76. doi: 10.1007/s00417-009-1156-9. Epub 2009 Aug 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验